Updated
The most significant concentration Enliven Therapeutics discloses is ELVN-001, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Enliven Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'we are substantially dependent on ELVN-001. If we are unable to advance ELVN-001 through clinical development, obtain regulatory approval and ultimately commercialize or license ELVN-001'”
“10-K Item 1: 'our good manufacturing practice ("GMP") APIs from Pharmaron'”
The company's concentration profile is dominated by two high-share exposures that together define the investable thesis. The first is pipeline concentration: the company is substantially dependent on ELVN-001, its lead program, with all other programs still in preclinical or discovery stages at the time of filing. This is a mixed exposure — structural in that clinical-stage biotechs characteristically concentrate resources on their most advanced asset, but carrying a dependency dimension since the company's ability to create value hinges on advancing, obtaining regulatory approval for, and ultimately commercializing or licensing that single compound. The second exposure is a manufacturing dependency: good manufacturing practice APIs for the lead program are supplied by Pharmaron, a high-share dependency on a single contract manufacturer. For a pre-revenue clinical-stage company, any disruption at the API supplier — regulatory, operational, or logistical — could delay trials and set back the development timeline. The two exposures reinforce each other: the entire value of the enterprise depends on ELVN-001's clinical success, and that clinical program's supply chain runs through a single external manufacturer. There is no customer, geographic, or product diversification to offset these concentrations. On balance, this is a concentrated single-asset clinical story with a supply chain dependency at the manufacturing level, and both factors should be weighted heavily in any risk assessment.
For the engine’s reasoning on ELVN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ELVN● | Enliven Therapeutics, Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.